Anti-inflammatory effects of carbon monoxide-releasing molecule on trinitrobenzene sulfonic acid-induced colitis in mice

Digestive Diseases and Sciences

Volumn 59, Issue 6, 2014, Pages 1142-1151

  Fukuda, Wataru ^a   Takagi, Tomohisa ^a   Katada, Kazuhiro ^a   Mizushima, Katsura ^a   Okayama, Tetsuya ^a   Yoshida, Naohisa ^a   Kamada, Kazuhiro ^a   Uchiyama, Kazuhiko ^a   Ishikawa, Takeshi ^a   Handa, Osamu ^a   Konishi, Hideyuki ^a   Yagi, Nobuaki ^a   Ichikawa, Hiroshi ^b   Yoshikawa, Toshikazu ^a   Cepinskas, Gediminas ^c   Naito, Yuji ^a   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

2,4,6 Trinitrobenzene sulfonic acid (TNBS) induced colitis; Carbon monoxide (CO); CO releasing molecule (CORM); Inflammatory bowel disease (IBD)

Indexed keywords

ANTIINFLAMMATORY AGENT; CARBON MONOXIDE RELEASING MOLECULE 3; GAMMA INTERFERON; INTERLEUKIN 17; MESSENGER RNA; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DESCENDING COLON; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; INFLAMMATORY CELL; INTERFERON PRODUCTION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; SUPERNATANT; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIMETABOLITES; CARBON MONOXIDE; COLITIS; COLON; CYTOKINES; GENE EXPRESSION REGULATION; MALE; MICE; ORGANOMETALLIC COMPOUNDS; PEROXIDASE; SPLEEN; TRINITROBENZENESULFONIC ACID;

EID: 84902286425     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-3014-1     Document Type: Article

References (51)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. (Pubitemid 47123518)
2. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517-554. (Pubitemid 27238886)
3. Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol. 1999;276:L688-L694. (Pubitemid 29211371)
4. Kaizu T, Ikeda A, Nakao A, et al. Protection of transplant-nduced hepatic ischemia/reperfusion injury with carbon monoxide via MEK/ERK1/2 pathway downregulation. Am J Physiol Gastrointest Liver Physiol. 2008;294:G236-G244.
5. Nakao A, Kimizuka K, Stolz DB, et al. Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Am J Pathol. 2003;163:1587-1598. (Pubitemid 37175105)
6. Nakao A, Toyokawa H, Abe M, et al. Heart allograft protection with low-dose carbon monoxide inhalation: effects on inflammatory mediators and alloreactive T-cell responses. Transplantation. 2006;81:220-230.
7. Neto JS, Nakao A, Kimizuka K, et al. Protection of transplant-nduced renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol. 2004;287:F979-F989. (Pubitemid 39391095)
8. Takagi T, Naito Y, Inoue M, et al. Inhalation of carbon monoxide ameliorates collagen-induced arthritis in mice and regulates the articular expression of IL-1beta and mcp-1. Inflammation. 2009;32:83-88.
9. Tsui TY, Obed A, Siu YT, et al. Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic energy metabolism. Shock. 2007;27:165-171. (Pubitemid 46105833)
10. Hegazi RA, Rao KN, Mayle A, et al. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med. 2005;202:1703-1713. (Pubitemid 41815876)
11. Zuckerbraun BS, Otterbein LE, Boyle P, et al. Carbon monoxide protects against the development of experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2005;289: G607-G613. (Pubitemid 41216400)
12. Takagi T, Naito Y, Mizushima K, et al. Increased intestinal expression of heme oxygenase-1 and its localization in patients with ulcerative colitis. J Gastroenterol Hepatol. 2008;23:S229-S233.
13. Naito Y, Takagi T, Uchiyama K, et al. Heme oxygenase-1: a novel therapeutic target for gastrointestinal diseases. J Clin Biochem Nutr. 2011;48:126-133.
14. Takagi T, Naito Y, Mizushima K, et al. Inhalation of carbon monoxide ameliorates TNBS-induced colitis in mice through the inhibition of TNF-α expression. Dig Dis Sci. 2010;55:2797-2804.
15. Boyko EJ, Koepsell TD, Perera DR, et al. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med. 1987;12:707-710. (Pubitemid 17036475)
16. Jick H, Walker AM. Cigarette smoking and ulcerative colitis. N Engl J Med. 1983;308:261-263. (Pubitemid 13174359)
17. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9:728-743.
18. Guo Y, Stein AB, Wu WJ, et al. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol. 2004;286:H1649-H1653. (Pubitemid 38525450)
19. De Backer O, Elinck E, Blanckaert B, et al. Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress. Gut. 2009;58:347-356.
20. Motterlini R, Clark JE, Foresti R, et al. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res. 2002;90:E17-E24.
21. Taillé C, El-Benna J, Lanone S, et al. Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle. J Biol Chem. 2005;280:25350-25360. (Pubitemid 40962237)
22. Clark JE, Naughton P, Shurey S, et al. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ Res. 2003;93:e2-e8.
23. Uchiyama K, Naito Y, Takagi T, et al. Carbon monoxide enhance colonic epithelial restitution via FGF15 derived from colonic myofibroblasts. Biochem Biophys Res Commun. 2010;391:1122-1126.
24. Cepinskas G, Katada K, Bihari A, et al. Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammation in the liver of septic mice. Am J Physiol Gastrointest Liver Physiol. 2008;294:G184-G191.
25. Higashimura Y, Naito Y, Takagi T, et al. Oligosaccharides from agar inhibitmurine intestinal inflammation through the induction of heme oxygenase-1 expression. J Gastroenterol. 2013;48:897-909.
26. Harusato A, Naito Y, Takagi T, et al. BTB and CNC homolog 1 (Bach1) deficiency ameliorates TNBS colitis in mice: role of M2 macrophages and heme oxygenase-1. Inflamm Bowel Dis. 2013;19:740-753.
27. Mizuguchi S, Stephen J, Bihari R, et al. CORM-3-derived CO modulates polymorphonuclear leukocyte migration across the vascular endothelium by reducing levels of cell surface-bound elastase. Am J Physiol Heart Circ Physiol. 2009;297:H920-H929.
28. Hervera A, Leánez S, Motterlini R, et al. Treatment with carbon monoxide-releasing molecules and an HO-1 inducer enhances the effects and expression of μ-opioid receptors during neuropathic pain. Anesthesiology. 2013;118:1180-1197.
29. Lancel S, Montaigne D, Marechal X, et al. Carbon monoxide improves cardiac function and mitochondrial population quality in a mouse model of metabolic syndrome. PLoS One. 2012;7:e41836.
30. Tayem Y, Johnson TR, Mann BE, et al. Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. Am J Physiol Renal Physiol. 2006;290:F789-F794. (Pubitemid 43724937)
31. McCafferty DM, Miampamba M, Sihota E, et al. Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut. 1999;45:864-873.
32. Sugimoto N, Rui T, Yang M, et al. Points of control exerted along the macrophage-endothelial cell-polymorphonuclear neutrophil axis by PECAM-1 in the innate immune response of acute colonic inflammation. J Immunol. 2008;181:2145-2154.
33. Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease. J Immunol. 1996;157:2174-2185.
34. Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol. 1986;251:G567-G574.
35. Takagi T, Naito Y, Uchiyama K, et al. Carbon monoxide liberated from carbon monoxide-releasing molecule exerts an antiinflammatory effect on dextran sulfate sodium-induced colitis in mice. Dig Dis Sci. 2011;56:1663-1671.
36. Sheikh SZ, Hegazi RA, Kobayashi T, et al. An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol. 2011;186:5506-5513.
37. Lunney PC, Leong RW. Review article: ulcerative colitis, smoking and nicotine therapy. Aliment Pharmacol Ther. 2012;36:997-1008.
38. Motterilini R, Mann BE, Johnson TR, et al. Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. Curr Pharm Des. 2003;9:2525-2539. (Pubitemid 37236371)
39. Katada K, Bihari A, Mizuguchi S, et al. Carbon monoxide liberated from CO-releasing molecule (CORM-2) attenuates ischemia/reperfusion (I/R)-induced inflammation in the small intestine. Inflammation. 2010;33:92-100.
40. Bani-Hani MG, Greenstein D, Mann BE, et al. Modulation of thrombin-induced neuroinflammation in BV-2 microglia by carbon monoxide-releasing molecule 3. J Pharmacol Exp Ther. 2006;318:1315-1322. (Pubitemid 44268341)
41. Bagul A, Hosgood SA, Kaushik M, et al. Carbon monoxide protects against ischemia-reperfusion injury in an experimental model of controlled nonheartbeating donor kidney. Transplantation. 2008;27:576-581.
42. Sener A, Tran KC, Deng JP, et al. Carbon monoxide releasing molecules inhibit cell death resulting from renal transplantation related stress. J Urol. 2013;190:772-778.
43. Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol. 2007;42:787-798. (Pubitemid 47617456)
44. Naito Y, Takagi T, Yoshikawa T. Neutrophil-dependent oxidative stress in ulcerative colitis. J Clin Biochem Nutr. 2007;41:18-26. (Pubitemid 47266169)
45. Naito Y, Uchiyama K, Takagi T, et al. Therapeutic potential of carbon monoxide (CO) for intestinal inflammation. Curr Med Chem. 2012;19:70-76.
46. Freitas A, Alves-Filho JC, Secco DD, et al. Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. Br J Pharmacol. 2006;149:345-354. (Pubitemid 44582241)
47. Bergstraesser C, Hoeger S, Song H, et al. Inhibition of VCAM-1 expression in endothelial cells by CORM-3: the role of the ubiquitin-proteasome system, p38, and mitochondrial respiration. Free Radic Biol Med. 2012;52:794-802.
48. Megías J, Busserolles J, Alcaraz MJ. The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells. Br J Pharmacol. 2007;150:977-986. (Pubitemid 46625094)
49. Lee SS, Gao W, Mazzola S, et al. Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells. FASEB J. 2007;21:3450-3457. (Pubitemid 350075135)
50. Brusko TM, Wasserfall CH, Agarwal A, et al. An integral role for heme oxygenase-1 and carbon monoxide in maintain peripheral tolerance by CD4 + CD25 + regulatory T cells. J Immunol. 2005;174:5181-5186. (Pubitemid 40593154)
51. Onyiah JC, Sheikh SZ, Maharshak N, et al. Carbon monoxide and heme oxygenase-1 prevent intestinal inflammation in mice by promoting bacterial clearance. Gastroenterology. 2012;144:789-798.